Evaluation of PKU Sphere Liquid

Vitaflo

Status

Completed

Conditions

Phenylketonurias

Treatments

Dietary Supplement: PKU sphere liquid

Study type

Interventional

Funder types

Industry

Identifiers

NCT05096988

20/NW/0273 (Other Identifier)

MCT-GMPL-2018-02-21

271801 (Other Identifier)

Details and patient eligibility

About

PKU Sphere Liquid is a prospective, open-label, acceptability study to evaluate PKU sphere liquid in up to 15 participants aged 3 and above for the dietary management of PKU over 31 days.

Full description

PKU Sphere Liquid is a newly-developed Food for Special Medical Purposes (FSMP) designed for the dietary management of patients with phenylketonuria (PKU).

PKU sphere liquid is a vanilla flavoured, ready-to-drink, low phenylalanine protein substitute containing a blend of casein glycomacropeptide (GMP) isolate, essential and non-essential amino acids, carbohydrate, fat, vitamins, minerals, and Docosachexaenoic acid (DHA).

This is a feasibility study designed to evaluate the acceptability, tolerance and adherence of children and adults consuming PKU sphere liquid.

Participants will be given a four-week supply of PKU Sphere Liquid and they will be asked to complete a daily diary and short questionnaire for four weeks to record information on: adherence, gastrointestinal tolerance, palatability and how the product is used.

Each participant will be on the trial for 31 days. This includes a 3-day baseline period and 28 days taking the study product. If deemed appropriate in each individual circumstance, the sponsor of the trial, Vitaflo International Ltd, will continue to supply the product free of charge at the end of the trial until available on prescription.

Enrollment

19 patients

Sex

All

Ages

3+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Diagnosis of PKU requiring a low protein diet and protein substitute.
Aged three (3) years and over
Already taking a minimum of one GMP based protein substitute per day or have previously taken one
Able to comply with the study protocol and take the study product, according to the opinion of the PI.
Willingly given, written, informed consent from patient or parent/guardian.
Willingly given, written assent (if appropriate).

Exclusion criteria

Inability to comply with the study protocol, in the opinion of the investigator.
Any co-morbidity, which, in the opinion of the investigator, would preclude participation in the study.
Diagnosis of persistent hyperphenylalaninaemia, or mild PKU not requiring dietary intervention with a low protein diet and protein supplement.
Unwilling/unable to take a GMP based protein substitute.
Women who are pregnant / breastfeeding at the start of the study or planning to become pregnant during the study period.

N.B.: Women who become pregnant unexpectedly during this study will be immediately withdrawn from the study.